Abstract
The Vision Loss Expert Group (VEEG) has recently reported that globally, 1.1 billion people live with vision loss and 90% of such people live in low- and middle-income countries (LMICs) [2]. This report further states that with the current strategy of eye care, changing trends in disease profiles, and increased longevity, the number of people with vision loss is likely to increase by 60%, from 1.1 billion to 1.7 billion, by 2050. The numbers of blind people (vision <3/60) will increase from the current 43 million to 61 million (42% increase); those with moderate to severe visual impairment (vision <6/18, but >3/60) will increase from the current 295 million to 474 million (61% increase); people with mild visual impairment (vision <6/12) will increase from the current 258 million to 360 million (39.5% increase), and those with near vision difficulties will increase from the current 510 million to 866 million (70% increase).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ophthalmic Drugs Market Expected to Reach $42,663 Million, Globally by 2023: Allied Market Research. https://www.alliedmarketresearch.com/ophthalmic-drugs-market
Vision Atlas 2020. www.iapb.org. Accessed 28 Dec 2020.
Burton MJ, Faal HB, Ramke J, Ravilla T, Holland P, Wang N, et al. Announcing the Lancet Global Health Commission on Global Eye Health. Lancet. Dec 2019;7(12):E1612–3.
The Lancet. A vision for Universal Eye Health. Editorial. Oct 2019;394(10207):1388.
Pharma 2020: The vision. Pwc global market report. www.pwc.com. Accessed Nov 2020.
Narayanan V. Pharmaceutical ophthalmic market perspectives in India and emerging trends. Clin Exp Vis Eye Res J. 2018;1(1):35–7.
Global ophthalmic drugs market size, share, trends and growth analysis report – segmented by therapeutic class, product type, distribution channel, disease, indications, dosage form, technology, region – industry forecast (2020 to 2025). https://www.marketdataforecast.com/market-reports/ophthalmic-drugsmarket. Accessed Oct 2020.
Ophthalmic Drug Market Overviews. Allied Market Research. Accessed Dec 2020 https://www.alliedmarketresearch.com/ophthalmic-drugs-market
Global Ophthalmology Drugs Market Opportunities and Strategies (2019 to 2030) - COVID-19 Impact and Recovery. www.globenewswire.com/newsrelease/2020/05/28/2040100/0/en/Global-Ophthalmology-Drugs-Market-Opportunitiesand-Strategies-2019-to-2030. Accessed Oct 2020.
Serle JB, Katz LJ, McLaurin E, et al. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients with Elevated Intraocular Pressure: Rho Kinase Elevated IOP treatment trial 1 and 2 (ROCKET-m 1 and ROCKET-2). Am J Ophthalmol. 2018;186:116–27.
Weinreb RN, Realine T, Varma R. Latanoprostene bunod, a dual-acting nitric oxide donating prostaglandin analog for lowering of intraocular pressure. US Ophthalmic Rev. 2016;9:80–7. https://doi.org/10.17925/USOR.2016.09.02.80.
Asia pacific ophthalmic drugs market research report – segmented therapeutic class, product type, distribution channel, by disease indication, by dosage form, by technology by country – industry analysis, size, share, growth, trends, and forecasts (2019–2024). https://www.marketdataforecast.com/marketreports/asia-pacificophthalmic-drugs-market. Accessed Oct 2020
An overview of eye care market in ASEAN. An overview of eye care market in ASEAN. www.hmadvisory.net/assets/pdf/Anoverview-of-Eye care-Market-in-ASEAN-2013-22102013.pdf. Accessed November 2020.
Das T. Blindness and visual impairment profile and rapid assessment of avoidable blindness in south east asia: analysis of new data. 2017 APAO Holmes lecture. Asia Pac J Ophthalmol (Phila). 2018;7:312–5.
IMS-IQVIA and Country Internal Audit 2020 India and 2019 SEAR countries reports: market share, value and growth of ophthalmic pharmaceuticals data on file: Sun Pharmaceuticals Ltd.
Ophthalmic Drug Price India and SEAR countries Data on File: Sun Pharmaceuticals Ltd.
Pharmaceutical industry of Bangladesh report. www.arx.cfa/~/media/2A85F9B2CEAB43CFAF325AB54F3EF404.ashx. Accessed Nov 2020.
India Pharma 2020 Propelling Access and Acceptance summary: Realizing True Potential: Pharmaceutical and Medical Products Practice. McKinsey report. www.mckinsey.com/~/media/mckinsey/dotcom/client_service/Pharma%20and%2. Accessed Nov 2020.
Ophthalmic comprehensive reports: 2020 India ophthalmic market report: A regional analysis for 2019 to 2025, April, 2020. https://www.marketscope.com/pages/reports/177/2020-india-ophthalmicmarket-report-a-regional-analysis-for2019-to-2025-april-2020. Accessed Nov 2020
Sun Pharma launches first branded ophthalmic product, BromSite™, in USA. World Pharma Today Apr 2016. www.worldpharmatoday.com/news/sun-pharmalaunches-firstbranded-ophthalmic-product. Accessed Dec 2020.
Sun Pharma introduces access program for patients prescribed XELPROS in the U.S. Biospace July 2019. www.biospace.com. Accessed Dec 2020.
Sun Pharma Launches CEQUA for The Treatment Of Dry Eye Disease in the U.S. Businesswire Oct 2019. www.businesswire.com/news/home/20191013005028/en/Sun-PharmaLaunchesCEQUA-for-the-Treatment-of-Dry-Eye-Disease-in-the-U.S. Accessed Dec 2020.
IQVIA Nepal Audit July 2019 Market and Prescription Data on File.
Essential medicine. www.who.int. Accessed 28 Dec 2020.
Persaud N, Jiang M, Shaikh R, et al. Comparison of essential medicines lists in 137 countries. Bull World Health Organization. 2019;97:394–404C. https://doi.org/10.2471/BLT.18.222448.
World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
SEAR-WHO countries, policies, profiles and information worksheet. www.google.com. Accessed Dec 2020.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Sharma, S., Narayanan, V., Mahajan, M., Mohan, Y.S.V.S.N. (2021). Ophthalmic Pharmaceutical Markets South-East Asia Region Perspective 2020. In: Das, T., Nayar, P.D. (eds) South-East Asia Eye Health. Springer, Singapore. https://doi.org/10.1007/978-981-16-3787-2_35
Download citation
DOI: https://doi.org/10.1007/978-981-16-3787-2_35
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-3786-5
Online ISBN: 978-981-16-3787-2
eBook Packages: MedicineMedicine (R0)